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Abstract
Objective: Deficiency of pyruvate dehydrogenase complex (PDHC) is the most
common genetic disorder leading to lactic acidosis. PDHC deficiency is geneti-
cally heterogenous and most patients have defects in the X-linked E1-a gene
but defects in the other components of the complex encoded by PDHB, PDHX,
DLAT, DLD genes or in the regulatory enzyme encoded by PDP1 have also
been found. Phenylbutyrate enhances PDHC enzymatic activity in vitro and in
vivo by increasing the proportion of unphosphorylated enzyme through inhibi-
tion of pyruvate dehydrogenase kinases and thus, has potential for therapy of
patients with PDHC deficiency. In the present study, we investigated response
to phenylbutyrate of multiple cell lines harboring all known gene defects result-
ing in PDHC deficiency. Methods: Fibroblasts of patients with PDHC defi-
ciency were studied for their enzyme activity at baseline and following
phenylbutyrate incubation. Drug responses were correlated with genotypes and
protein levels by Western blotting. Results: Large deletions affecting PDHA1
that result in lack of detectable protein were unresponsive to phenylbutyrate,
whereas increased PDHC activity was detected in most fibroblasts harboring
PDHA1 missense mutations. Mutations affecting the R349-a residue were direc-
ted to proteasome degradation and were consistently unresponsive to short-
time drug incubation but longer incubation resulted in increased levels of
enzyme activity and protein that may be due to an additional effect of phen-
ylbutyrate as a molecular chaperone. Interpretation: PDHC enzyme activity
was enhanced by phenylbutyrate in cells harboring missense mutations in
PDHB, PDHX, DLAT, DLD, and PDP1 genes. In the prospect of a clinical trial,
the results of this study may allow prediction of in vivo response in patients
with PDHC deficiency harboring a wide spectrum of molecular defects.
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Introduction
Deficiency of nuclear-encoded pyruvate dehydrogenase
complex (PDHC) is one of the most common inborn
errors of mitochondrial energy metabolism.1 PDHC cata-
lyzes within mitochondria conversion of pyruvate to ace-
tyl coenzyme A, a key regulatory step in the central
pathway of energy production. This reaction is particu-
larly important in brain which has obligatory requirement
for aerobic glucose oxidation. Most patients with PDHC
deficiency show progressive neurological degeneration and
either persistent or episodic elevations of lactate in blood,
cerebrospinal fluid (CSF), or both. Affected patients pres-
ent with a graded spectrum of severity ranging from the
most severe congenital brain malformations with over-
whelming lactic acidemia and death in the neonatal per-
iod to development of Leigh syndrome or to a milder
form with carbohydrate induced ataxia.1–3 PDHC is a
multienzyme complex consisting of (1) thiamine diphos-
phate (ThDP)-dependent pyruvate dehydrogenase (E1), a
heterotetrameric (a2b2) protein; (2) dihydrolipoamide
acetyltransferase (E2), which forms the structural core of
the complex; and (3) FAD-containing dihydrolipoamide
dehydrogenase (E3), which is integrated into the complex
by an E3-binding protein (E3BP). PDHC is regulated
through phosphorylation of E1-a subunit by four pyru-
vate dehydrogenase kinase (PDK) isoforms that inactivate
the enzyme,4 whereas dephosphorylation by pyruvate
dehydrogenase phosphatases (PDP1 and PDP2) restore
PDHC activity.5 PDHC deficiency may be due to muta-
tions in the genes PDHA1, PDHB, PDHX, DLAT, and
DLD encoding for E1-a, E1-b, E3BP, E2, and E3, respec-
tively, or to mutations of PDP1 gene encoding pyruvate
dehydrogenase phosphatase 1.1,2 The most common form
is due to mutations of PDHA1 gene located on the short
arm of the X chromosome.6 We have previously shown
that phenylbutyrate increases residual activity of PDHC
by increasing the proportion of unphosphorylated enzyme
and has potential for therapy of PDHC deficiency and
systemic lactic acidosis.7 In the present study, to correlate
in vitro drug response to the type of mutation, we inves-
tigated phenylbutyrate responsiveness on several cell lines
harboring PDHA1 mutations. In addition, we investigated
phenylbutyrate response in patients’ fibroblasts harboring
defects in all remaining components of the multienzyme
complex and in PDP1 gene.
Material and Methods
PDHC activity was measured at baseline and after incuba-
tion with 1 mmol/L phenylbutyrate (Amonaps; Swedish
Orphan International Lab, Stockholm, Sweden) in Dul-
becco’s Modified Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) for 24 h or 5 days on
mitochondrial extracts prepared from synchronized fibro-
blasts (cultured in DMEM and 1% FBS for 24 h), as pre-
viously described.7,8 PDHC enzyme activity was calculated
as nmol min1 mg1 of protein and expressed as fold
increase of activity in cells treated with phenylbutyrate
over untreated cells (at least n = 2 for each treatment).
Statistical significance was computed using the Student’s
two-tailed test. P < 0.05 was considered statistically signif-
icant.
Fibroblasts were analyzed for expression of proteins of
PDHC with the following primary monoclonal antibodies:
anti-PDH-E1a (9H9AF5), anti-PDH-E1b (17A5E2H8),
anti-PDH-E2 (15D3G9C11), anti-E3BP (13G2AE2BH5),
and anti-PDH-E3 (EPR6635). The anti-PDH-E1a, anti-
PDH-E1b, anti-PDH-E2, anti-E3BP mixed in a cocktail
(#ab110416), and the anti-PDH-E3 (#ab133551) were pur-
chased from Abcam (Cambridge, UK). The antibodies
phosphodetect anti-PDH-E1a (pSer264; AP1062), phospho-
detect anti-PDH-E1a (pSer203; AP1063), phosphodetect
anti-PDH-E1a (pSer271; AP1064) were from Calbiochem
(Darmstadt, Germany) and the anti-cytochrome c oxidase
IV (COXIV; #4844) from Cell Signaling Technology Inc
(Danvers, MA, USA). Horseradish peroxidase (HRP)-con-
jugated secondary antibodies (ECL rabbit IgG, HRP-linked
whole antibody from donkey [GE Healthcare, Milan, Italy
NA934] and ECL anti-mouse IgG, HRP-linked species-spe-
cific whole antibody from sheep [GE Healthcare, NA931])
were diluted in 5% dried skim milk and in 1% bovine
serum albumin (BSA) in tris-buffered saline-Tween20.
Protein bands were visualized with a chemiluminescence
detection system (Thermo Fisher Scientific Inc., Rockford,
IL, USA) and band intensities were quantified with Quan-
tity One-4.6.7 Basic (1-D Analysis Software; Bio-Rad Labo-
ratories Inc. Hercules, CA, USA).
For proteasome inhibition, cells were cultured in
DMEM supplemented with 10% FBS and after the 5-day
treatment with 1 mmol/L of phenylbutyrate, were incu-
bated with 40 lmol/L MG132 (Selleckchem, Munich,
Germany) or Dimethyl Sulfoxide (DMSO) for 6 h,
washed once with cold phosphate-buffered saline (PBS),
and scraped with RIPA buffer (50 mmol/L Tris-HCl pH
7.4, 150 mmol/L NaCl, 1% Triton X-100, 1 mmol/L
Ethylenediaminetetraacetic acid (EDTA) pH 8.0, 0.1%
SDS) containing complete protease inhibitor cocktail
(Sigma, St. Louis, MO, USA). Samples were incubated for
20 min at 4°C, centrifuged at 16,000 g for 10 min and
cell lysates were used for Western blot.
Results
We analyzed PDHC activity in untreated and phenylbuty-
rate-treated skin fibroblasts from patients harboring all
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known molecular defects responsible for PDHC defi-
ciency, that are, mutations in PDHA1, PDHB, PDHX,
DLAT, DLD, and PDP1 genes (Table 1). As a control,
enzyme activity was measured at baseline and after phen-
ylbutyrate in fibroblasts from a control subject. Among
16 cell lines with PDHA1 missense mutations (Table 1),
11 cell lines showed a significant increase in enzyme activ-
ity following incubation with phenylbutyrate and had
detectable E1-a protein by Western blotting (Fig. 1A and
B). Fibroblasts from nine male patients harboring mis-
sense (p.P221L, p.R234G, p.G249R, p.R349C, p.R349H),
Table 1. PDHC-deficient fibroblasts.
Cell
line Gender
Enzyme
activity
(% mean
control)
Allele 1
nucleotide
(protein)a
Allele 2
nucleotide
(protein)a
PDHA1 mutations
1b Male 62% c.749C>T
(p.P221L)
–
2c Male 46% c.787C>G
(p.R234G)
–
3b Male 56% c.832G>C
(p.G249R)
–
4c Male 21% c.1132G>C
(p.R349C)
–
5b Male 45% c.1132C>T
(p.R349C)
–
6b Male 7% c.1133G>A
(p.R349H)
–
7b Male 18% c.1133G>A
(p.R349H)
–
8d Male 52% c.483C>T
(p.Y132Y)
–
9b Male 7% c.1050_1133dup84
(p.Q351_R378dup)
–
10 Female 47% c.302G>T
(p.C72F)
wt
11b Female 48% c.302G>T
(p.C72F)
wt
12b Female 30% c.355C>T
(p.R90W)
wt
13b Female 23% c.379C>T
(p.R98W)
wt
14b Female 83% c.787C>G
(p.R234G)
wt
15 Female 13% c.904C>T
(p.R273C)
wt
16b Female 21% c.904C>T
(p.R273C)
wt
17b Female 19% c.904C>T
(p.R273C)
wt
18 Female 57% c.924G>T
(p.Q279H)
wt
19b Female 35% c.498C>T
(p.I137I)
wt
20b Female 8% c.292-2A>G
(p.E98_Q170del)
wt
21 Female 38% c.1140_1162del
(p.N381SfsX43)
wt
22 Female 22% c.934_940del
(p.S312VfsX12)
wt
23b Female 19% 2.14 Mb deletion wt
PDHB mutations
24b Male 75% c.301A>G
(p.M101V)
c.301A>G
(p.M101V)
25b Male 70% c.301A>G
(p.M101V)
c.793-2A>G
(p.l266LfsX26)
(Continued)
Table 1. Continued.
Cell
line Gender
Enzyme
activity
(% mean
control)
Allele 1
nucleotide
(protein)a
Allele 2
nucleotide
(protein)a
26b Female 55% c.301A>G
(p.M101V)
c.301A>G
(p.M101V)
27 Female 26% c.497A>G
(p.Y137C)
c.497A>G
(p.Y137C)
PDHX mutations
28b Male 25% c.1426C>T
(p.R476X)
c.1426C>T
(p.R476X)
29b Male 41% c.1182+2T>C
(p.l386SfsX13)
c.1182+2T>C
(p.l386SfsX13)
30b Male 35% c.160+1G>A
(p.G27X)
c.965-1G>A
(p.D322AfsX6)
31b Female 25% c.620delC
(p.P207LfsX16)
c.620delC
(p.P207LfsX16)
32 Male 14% Exon 4 and
5 deletion
Exon 4 and 5
deletion
DLAT mutations
33 Female 13% c.1624-1626del
(p.V560del)
ND
DLD mutations
34b Male 28% c.858dup
(p.G287WfsX4)
c1174G>A
(p.V392M)
35e Male 27% c.105insA
(p.Y35X)
c.685G>T
(p.G229C)
PDP1 mutations
36f Male 33% c.851_853del
(p.L284del)
c.851_853del
(p.L284del)
wt, wild-type; ND, not determined.
aNucleotides are reported according to NCBI gene sequences
(NM_000284.3 for PDHA1, NM_000925.3 for PDHB, NM_003477.2
for PDHX, NM_001931.4 for DLAT, NM_000108.3 for DLD,
NM_001161781 for PDP1). The amino acid positions of the mutations
are reported considering the mature NCBI protein sequences
(NP_000275.1 for PDHA1 [361 amino acids], NP_000916.2 for PDHB
[329 amino acids], NP_003468.2 for E3BP [448 amino acids],
NP_001922.2 for DLAT [561 amino acids], NP_060914.2 for DLD [474
amino acids] NP_001155253.1 for PDP1 [466 amino acids]) after sig-
nal peptide cleavage. Patients previously described by bImbard et al.12,
cDeBrosse et al.3, dBoichard et al.10, eShaag et al.28, and fMaj et al.29.
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splicing (c.483C>T), or truncating (p.Q351_R378dup)
mutations were studied (Table 1, black bars in Fig. 1A).
Hemizygous cell lines from patients carrying missense
mutations p.P221L, p.R234G, and p.G249R (cell lines 1,
2, and 3) showed elevated PDHC activities (62%, 46%,
and 56% of control mean), detectable E1-a protein by
Western blotting, and were all responsive to phenylbuty-
rate (Fig. 1A and B, and Table 1). Four cell lines not
responsive to phenylbutyrate all carried PDHA1 missense
mutations affecting the R349-a residue, had relatively
lower levels of PDHC residual activity ranging from 7%
to 45%, and showed very low-to-undetectable levels of
protein E1-a by Western blotting (cell lines 4–7, Fig. 1A,
and Table 1). Lack of increase in PDHC activity following
phenylbutyrate incubation was also previously observed in
another cell line (designated as Pt 3) from an unrelated
patient also harboring a mutation affecting R349-a.7
It was previously shown that cells harboring the
p.R349C mutation were also unresponsive to short-term
incubation with dichloroacetate (DCA), a pyruvate analog
which increases PDHC activity.9 In contrast, sustained
DCA incubation reduced turnover of E1-a protein and
increased PDHC activity.9 Therefore, we investigated
longer incubation with phenylbutyrate in fibroblasts har-
boring mutations affecting R349-a (cell lines 4–7 and Pt
37) and found that 5-day drug incubation increased
PDHC enzyme activity (Fig. 2A). Following 5-days of
incubation with phenylbutyrate, we also observed an
increase in the amount of E1-a protein compared to
untreated cells (Fig. 2B). The ubiquitin-proteasome is the
major route for degradation of cell proteins and thus, we
investigated E1-a protein levels in fibroblast cell line 5,
carrying the p.R349C mutation, by inhibiting proteasome
activity with the MG132 proteasome inhibitor. Incubation
with MG132 increased E1-a protein to levels similar to
those observed in phenylbutyrate-treated cells but no fur-
ther increase in E1-a was observed in cells cotreated with
phenylbutyrate and MG132 (Fig. 2B). Taken together,
these results may indicate that E1-a harboring the
p.R349C mutation is degraded by the proteasome and
phenylbutyrate increases resistance of the mutated protein
to proteasome degradation.
The synonymous mutation c.483C>T (p.Y132Y) of cell
line 8 causes aberrant splicing in 40% of total cDNA with
exon 5 skipping predicted to result in a frameshift and
premature termination after the addition of 10 aberrant
amino acids (p.Arg141AlafsX11).10 Immunoblotting of
these fibroblasts resulted in detectable E1-a protein band
Figure 1. (A) PDHC activity in fibroblasts with PDHA1 mutations. PDHC activity is shown as fold increase in baseline activity after incubation with
phenylbutyrate. Bars indicate average  standard error of the mean; *P < 0.05. PDHC activity was increased in four of the nine fibroblast cell
lines from male patients shown as black bars and in 10 of the 14 fibroblast cell lines from female patients shown as white bars. (B) Western
blotting of skin fibroblasts with PDHA1 mutations with a cocktail of antibodies recognizing E1-a (43 KDa), E1-b (39 kDa), E2 (69 kDa), and E3BP
(54 kDa) proteins. Western blotting for cytochrome c oxidase (COX; 17 kDa) was performed as mitochondrial marker. The PDHA1 mutations of
the corresponding patient cell lines are shown in Table 1. wt, wild-type control fibroblasts.
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of normal size expressed from the proportion of correctly
spliced mRNA (Fig. 1A).10 Phenylbutyrate likely increased
enzyme activity of normal E1-a enzyme expressed from
the correctly spliced mRNA. The hemizygous cell line 9
from male patient carrying the c.1050_1133dup84 resulted
in very low PDHC activity, in no detectable E1-a protein,
and phenylbutyrate failed to increase significantly PDHC
activity (Fig. 1A and B).
Fibroblasts from 14 female patients harboring missense
(p.C72F, p.R90W, p.R98W, p.R234G, p.R273C,
p.Q279H), splicing (c.498C>T), or truncating (p.E98_
Q170del, p.S312VfsX12, p.N381SfsX43, 2.15 Mb deletion)
mutations were studied (Table 1, white bars in Fig. 1A).
Cell lines with PDHA1 mutations from female patients
are expected to express both wild-type and mutant
alleles.6 Furthermore, skewed X-inactivation is found in
approximately one fourth of skin fibroblasts from PDHC-
deficient patients.6 Thus, PDHC activity in cells from
female patients results from both residual activity of the
enzyme encoded by the mutant allele and the activity of
the enzyme expressed from the wild-type allele. Phenylbu-
tyrate increases PDHC activity in wild-type cells
(Fig. 1A)7 and thus, it is not possible to determine
whether phenylbutyrate increases the activity of the
enzyme encoded by the wild-type or by the mutated allele
in cells from female patient. Nine fibroblast cell lines with
missense mutations resulted in variable PDHC activities
ranging from 13% to 83%, detectable levels of E1-a pro-
tein, and were all responsive to phenylbutyrate incubation
(Table 1, white bars in Fig. 1A and B). The p.R273C
mutation present in cell lines 15–17 results in normal lev-
els of E1-a immunoreactive protein and catalytically inac-
tive enzyme11 and thus, phenylbutyrate is likely increasing
enzyme activity of E1-a expressed from the wild-type
allele. Cell line harboring the p.Q279H mutation showed
low levels of E1-a protein by Western blotting and was
unresponsive to phenylbutyrate (cell line 18, Fig. 1A and
B, Table 1).
The synonymous mutation c.498C>T (p.I137I) in cell
line 19 from a female patient causes aberrant splicing in
40% of total cDNA with exon 5 skipping predicted to
result in a frameshift with premature termination after
the addition of 10 aberrant amino acids
(p.Arg141AfsX11).10 This mutation results in detectable
E1-a protein by Western blotting of skin fibroblasts
(Fig. 1B). This protein band is likely a combination of
the products of the wild-type allele and the correctly
spliced protein from the allele carrying the mutation.
Likely, phenylbutyrate is increasing the activity of the
enzyme expressed from the wild-type allele and from
the proportion of enzyme derived from the correctly
spliced mRNA expressed from the mutant allele
(Fig. 1A). Cell line 22 from a female patient harboring
the mutation c.934_940del and with 22% of residual
enzyme activity had a significant 2.8-fold increase in
PDHC activity after incubation with phenylbutyrate and
showed detectable levels of E1-a by Western blotting
(Table 1, Fig. 1A and B). Three cell lines of fibroblasts
harboring splicing mutation or deletions (fibroblast cell
lines 20, 21, and 23) carrying the mutations c.292-
2A>G, c.1140_1162del, and a 2.14 Mb deletion, respec-
tively, showed low-to-undetectable levels of E1-a protein
and low PDHC activity (8–38%) and were unresponsive
to phenylbutyrate (Fig. 1A and B). The absence or the
low levels of E1-a protein by Western blotting suggests
occurrence in these cell lines of skewed X-inactivation
favoring the mutant allele that could explain the lack of
response to phenylbutyrate.
Figure 2. (A) PDHC activity in fibroblasts with mutations affecting R349 residue of E1-a protein following shorter (1 day) and longer (5 days)
phenylbutyrate incubations. (B) Western blotting for E1-a (43 kDa), E1-b (39 kDa), and E2 (69 kDa) protein of cell line 5 harboring p.R349C
mutation incubated with either vehicle, phenylbutyrate, MG132, or a combination of phenylbutyrate and MG132. Cytochrome c oxidase (COX;
17 kDa) was used as mitochondrial control marker.
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So far, 12 PDHB mutations have been reported and
four mutations, including the p.M101V found in patients
of North African descent,12 clustered in the same
region.12–14 We investigated phenylbutyrate in four cell
lines from patients harboring PDHB mutations (cell lines
24–27, Table 1) including the p.M101V mutation, and
three of them showed a statistically significant increase in
PDHC activity after phenylbutyrate incubation (Fig. 3A).
Three of these cell lines with PDHB mutations showed a
reduction in E1-b protein by Western blotting, whereas
the nonresponder cell line (cell 27) had E1-b levels simi-
lar to wild-type levels (Fig. 3B). In two of the three cell
lines responding to phenylbutyrate in terms of increased
enzyme activity (cell lines 24 and 25), an increase in E1-b
protein was observed by Western blotting after phenylbu-
tyrate incubation (Fig. 3B). In the three cell lines that
responded to phenylbutyrate in terms of increased PDHC
activity, a reduction in phosphorylated E1-a levels was
observed, whereas cell line 27 that failed to respond to
phenylbutyrate did not show a reduction in phosphory-
lated E1-a levels (Figs. 3B, S1).
The E3BP lacks catalytic activity and has a structural
role in the formation of the enzyme complex binding E3
to E2. Mutations in PDHX gene encoding E3BP are the
second most common cause of PDHC deficiency2,12 and
the vast majority of the mutations are aberrant splicing
or nonsense mutations.12 In this study, we investigated
five cell lines harboring mutations in PDHX gene that all
carried nonsense mutations or deletions and showed
enzyme activity ranging from 14% to 41% (cell lines 28–
32, Table 1, Fig. 3A and C). Two of the cell lines (31 and
32, Table 1) harboring a single nucleotide deletion leading
to frameshift or an exon 4 and 5 deletion did not show
detectable E3BP by Western blotting (Fig. 3C). All five
Figure 3. (A) PDHC activity in fibroblasts with PDHB, PDHX, DLD, or PDP1 mutations. PDHC activity is shown as fold increase in baseline activity
following incubation with phenylbutyrate. Bars indicate average  standard error of the mean; *P < 0.05. Western blotting for E1-a (43 kDa), E1-
b (39 kDa), E2 (69 kDa), and E3BP (54 kDa) proteins of skin fibroblasts with PDHB (B), PDHX (C), or DLAT (D) mutations. (E) Western blotting for
E3 protein of cell lines 34 and 35 harboring DLD mutations. PDHC phosphorylation was evaluated with an antibody against the phosphorylated
E1-a (E1-a-Ser264). Cytochrome c oxidase (COX; 17 kDa) was used as mitochondrial marker. (F) Western blotting with antibodies against the
three phosphorylated sites of E1-a or total E1-a in fibroblast cell line 36 harboring a homozygous PDP1 mutation. wt1, control 1; wt2, control 2.
The PDHB, PDHX, DLD, or PDP1 mutations for each cell lines are shown in Table 1.
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cell lines were found to be responsive to phenylbutyrate
with an average 1.4-fold increase in enzyme activity
(Fig. 3A). Phenylbutyrate incubation did not appear to
affect E3BP protein levels determined by Western blotting
and a reduction in phosphorylated E1a levels was
observed in four of six cell lines (Figs. 3E, S1).
One cell line with DLAT mutation was available for
analysis and a 1.3-fold increase enzyme activity was
detected in this cell line after incubation with phenylbuty-
rate (cell line 33, Table 1 and Fig. 3A). Fibroblasts of cell
line 33 had low enzyme activity and did not show detect-
able levels of E2 protein by Western blotting even after
incubation with phenylbutyrate (Fig. 3D). Only one
mutation was detected in this patient. It appears that
mutations in the gene encoding the E2 are rare cause of
PDHC deficiency.2,15–17 One patient previously reported
had undetectable E2 immunoreactive protein,16 whereas
two other patients were found to express reduced but
detectable levels of E2 protein.17 The clinical presentation
appeared to be more severe in the patient with undetect-
able E2 protein compared to the patients with detectable
E2 that had relatively mild symptoms and episodic dysto-
nia. DCA was previously shown to increase PDHC activ-
ity in fibroblasts of these patients with DLAT
mutations.17 Phenylbutyrate was also found to correct the
morphological, locomotor, and behavioral phenotype of
the noam631 zebrafish model carrying a missense DLAT
gene mutation.7 Thus, E2 defects resulting from DLAT
mutations appear to be responsive to phenylbutyrate. A
reduction in phosphorylated E1a levels was observed in
this cell line with DLAT mutation following phenylbuty-
rate incubation (Figs. 1, 3B).
We also investigated phenylbutyrate in two cell lines
harboring DLD mutations resulting in E3 deficiency and
both showed an average 1.4-fold increase in baseline
PDHC activity (cell lines 34 and 35, Table 1 and Fig. 3A).
Both cell lines expressed the E3 protein, as shown by
Western blotting with anti-E3 antibody (Fig. 3E). Clinical
and biochemical presentation of this disorder is different
from the common presentation of other PDHC
defects.18,19 E3 is a common component of all three mito-
chondrial multienzyme complexes, and DLD mutations
result in a disorder associated with a combination of fea-
tures of branched chain a-ketoacid dehydrogenase
(BCKDC), PDHC, and a-ketoglutarate dehydrogenase
complex (KGDC) deficiencies. Phenylbutyrate inhibits the
kinase of BCKDC (BDK) and PDKs7,20 and thus, it is
expected to result in improvements of both BCKDC and
PDHC activities. Like cell lines with other defects, a
reduction in phosphorylated E1a levels was observed in
cells with DLD mutations (Figs. 3B, S1).
Finally, we investigated one cell line with PDP1 muta-
tions that was found to respond to phenylbutyrate (cell
line 36, Table 1; Fig. 3A). Phosphorylation of E1-a occurs
at three serine residues (Ser264-a, site 1; Ser271-a, site 2;
and Ser203-a, site 3). As expected based on the deficiency
of the phosphatase activity, the amount of phosphorylated
E1-a in this cell line is increased compared to control
wild-type cell lines (Fig. 3F). Following phenylbutyrate
incubation, phosphorylated E1-a was significantly reduced
at all three phosphorylation sites (Fig. 3F) that is consis-
tent with the mechanism of action of phenylbutyrate
based on PDK inhibition.7
Discussion
Phenylbutyrate enhances PDHC activity in vitro and in
vivo by increasing the proportion of unphosphorylated
enzyme through inhibition of PDK. It also reduces lactic
acid in a mouse model of systemic lactic acidosis, and res-
cues the phenotype of a zebrafish PDHC-deficient disease
model.7 In the present study, we investigated the efficacy
of phenylbutyrate in PDHC-deficient cells harboring a
wide spectrum of genetic defects and we correlated geno-
types with drug response. We found that phenylbutyrate
increases PDHC activity in the majority of analyzed fibro-
blasts. Increased PDHC activity was detected in most of
the fibroblasts with PDHA1 missense mutations. Large
deletions or nonsense PDHA1 mutations resulting in no
detectable protein by Western blotting were in general not
responsive to phenylbutyrate. The gene encoding E1-a is
located on the X chromosome, yet males and females are
affected in approximately equal numbers due to the high
proportion of heterozygous females manifesting the dis-
ease. All male patients with PDHA1 mutations have some
degree of residual activity, whereas several female patients
have null mutations resulting in complete deficiency of
the enzyme subunit. It appears that complete PDHC defi-
ciency is incompatible with normal development in hemi-
zygous males but can be tolerated in heterozygous females
due to the proportion of cells expressing the normal X
chromosome. In cells from female patients, due to skewed
pattern of X-inactivation favoring the normal X chromo-
some, enzyme activity might be higher, even falling within
the normal range. In this context, the great majority of
mRNA molecules arise from the normal gene. Phenylbuty-
rate increases PDHC activity in wild-type cells7 and thus,
it is not possible to determine in cells from female patients
whether phenylbutyrate increases the activity of the
enzyme encoded by the wild-type or by the mutated allele.
Nevertheless, we cannot rule out that even an increase in
PDHC activity in cells expressing the normal allele might
be beneficial in patients with PDHC deficiency.
Cells harboring mutations affecting the R349-a residue
of the E1-a protein were consistently found to be unre-
sponsive to short-term incubation with phenylbutyrate
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but longer incubations resulted in increased activity.
These results indicate that in addition to the direct effect
on PDK,7 phenylbutyrate increases the stability of E1-a
protein, at least in cells harboring missense mutations
affecting the R349-a. This result is consistent with the
previously recognized function of phenylbutyrate as
chemical chaperone21 and with reduced E1-a protein
turnover observed with sustained DCA incubation in
addition to PDK inhibition by DCA.9,22,23
We found that mutations affecting PDHB, PDHX,
DLAT, and DLD genes were also responsive, thus poten-
tially broadening therapeutic applications of phenylbuty-
rate to patients that harbor all known defects of PDHC
deficiency. In these cell lines a reduction in phosphory-
lated E1-a protein levels was observed by Western blot-
ting, thus suggesting that like cells with PDHA1
mutations, the increase in enzyme activity in cells harbor-
ing these defects is dependent, at least in part, on changes
of phosphorylation status of the enzyme complex induced
by phenylbutyrate.
Similar to phenylbutyrate, DCA also increases PDHC
activity and is effective in reducing blood, CSF, and brain
lactate.24 However, in a controlled trial in children with
various forms of congenital lactic acidosis, chronic DCA
administration did not result in improvements of neuro-
logic problems and other clinical outcomes.25 Moreover,
DCA has raised some concerns because it has been associ-
ated with hepatocellular and peripheral nerve toxicity,
particularly in adults.26 In contrast, phenylbutyrate is a
drug already approved for use in humans, its safety pro-
file is well known,27 and thus it is attractive for therapy
of patients with PDHC deficiency.
Enzyme activity measured in skin fibroblasts exhibit
large variations among PDHC-deficient patients and does
not correlate with the predicted severity of the mutation
and cognitive outcomes, either in males or females.3 Nev-
ertheless, enzyme activity appears to correlate with sur-
vival at least in males with PDHA1 mutations3 and thus,
drug interventions aiming at increasing enzyme residual
activity have potential for achieving clinically relevant
results. However, it is unlikely that such drug interven-
tions will reverse pre-existing severe brain damage, such
as Leigh syndrome.
In summary, cells harboring PDHA1 gene mutations,
that are the most common defects accounting for 80–
90% of cases of PDHC deficiency with known muta-
tions,2,3,12 respond to phenylbutyrate, especially if they
carry missense mutations, have PDHC activity >10%, or
exhibit detectable protein by Western blotting. Therefore,
patients carrying these defects are candidates for such
drug intervention. Cell lines from patients carrying other
less common molecular defects also appear to be respon-
sive to phenylbutyrate.
In conclusion, the results of the present study may help
to predict whether a patient with PDHC deficiency will
be responsive to phenylbutyrate therapy based on the
affected gene, type, and location of the mutation.
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online version of this article:
Figure S1. Average intensities of Western blotting bands
of phosphorylated E1-a normalized for total E1-a from
two independent experiments of fibroblasts with PDHB,
PDHX, DLAT, and DLD mutations (Table 1) incubated
with phenylbutyrate or vehicle. *P < 0.05.
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